Market Cap: $1.3T
Market Cap: $1.3T
Open
$1,206.37
Prev. Close
$1,415.55
High
$1,213.00
Low
$1,184.02
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications.
Eli Lilly and Company trades on the New York Stock Exchange under the ticker LLY, priced in USD.
Eli Lilly and Company has a market capitalisation of $1.3T, based on its latest share price.
LLY trades at 46.73 times its trailing 12-month earnings.
Over the past 52 weeks LLY has traded between $850.51 and $1,475.25.
Yes. Eli Lilly and Company's dividend yields 0.48% at the current share price, paying out 22% of its earnings.
Highly profitable: keeps 31.9% of revenue as net profit.
The analyst consensus rating for LLY is Buy. Analysts' average 12-month price target of $1,323.13 implies 4% downside.
David A. Ricks is the CEO of Eli Lilly and Company, which is headquartered in Indianapolis.
Generated automatically from reported financial data. General information only, not financial advice.

Eli Lilly and Company ( LLY ) has firmly established itself as a leader in the pharmaceutical sector, particularly through its innovative treatments for obesity that have propelled the company into a…

Eli Lilly and Company ( LLY ) has emerged as a prominent player in the pharmaceutical industry, particularly in the rapidly growing obesity treatment market. The company's innovative approach, driven…

Eli Lilly's Expanding Dominance in Pharmaceuticals Eli Lilly and Company ( LLY ) has carved a substantial niche in the pharmaceutical industry, showcasing significant growth driven predominantly by it…

Eli Lilly and Company ( LLY ) is drawing attention as the latest developments come into focus. Eli Lilly and Company (LLY) has firmly established itself as a leader in the pharmaceutical market, parti…